Faraz Jafri

Mr. Faraz Jafri

The University of Texas At Austin Dell Medical School, Austin, Texas, USA
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2023 in Journal of Public Health
Verified
Journal Article
Closed access
PDF file
FJFaraz Jafri
Faraz Jafri
NANirupama Ancha
Nirupama Ancha
ARAnanya Roy
Ananya Roy
SASami Ahmad
Sami Ahmad
HRHamna Riaz
Hamna Riaz
CHCharles Hyman
Charles Hyman

24 December 2024 in Clinical and Translational Gastroenterology
Verified
Journal Article
Open access
SGSara Gottesman
Sara Gottesman
KXKaren Xiao
Karen Xiao
HNHang P. Nguyen
Hang P. Nguyen
EHElizabeth Hernandez
Elizabeth Hernandez
ESEmily Saweris
Emily Saweris
LFLinda A. Feagins
Linda A. Feagins
INTRODUCTION: Because biologic and small molecule therapy is expensive, payors have mandated preauthorizations for these medications, often resulting in a lengthy approval process. The aims of this study were to assess the frequency of and risk factors for delays in starting advanced therapies assessing insurance, care team, and patient-related factors. METHODS: Retrospective, multicenter study of patients with adult inflammatory bowel disease with prescriptions for an advanced therapy in 2 geographically distinct academic gastroenterology practices: one with and the other without a dedicated pharmacist. A priori, we defined a delay in starting therapy as >14 days between prescription and the first dose. Logistic regression analysis was performed to assess for risk factors for delay. RESULTS: A total of 388 patients were prescribed advanced therapies with 46.6% receiving their first dose within 14 days. Patients who were on time vs delayed were similar in baseline demographics, disease characteristics, and disease activity. After adjusting for confounders, 3 independent risk factors remained significant as predictors for delay: study site (OR = 5.2, 95% CI 2.894, 9.333), intravenous drug delivery as opposed to subcutaneous or oral (OR = 3.07, 95% CI 1.845, 5.099), and insurance denial (OR = 2.72, 95% CI 1.082, 6.825). DISCUSSION: In a multicenter study, we found that a delay between prescription and administration of the first dose of an advanced therapy is common, with > 50% of patients having the first dose delayed by > 2 weeks. Delays in starting therapy were significantly more likely if denied by insurance, given by intravenously induction, or at a study site without a dedicated pharmacist.

4 August 2023 in Cancers
Verified
Journal Article
Open access
PDF file
FJFaraz Jafri
Faraz Jafri
VPVishal R. Patel
Vishal R. Patel
JXJianhui Xu
Jianhui Xu
DPDaniel Polsky
Daniel Polsky
AGArjun Gupta
Arjun Gupta
SHSyed Mohammed Qasim Hussaini
Syed Mohammed Qasim Hussaini
Background: The Medicare Advantage program provides care to nearly half of Medicare beneficiaries, including a rapidly growing population of cancer survivors. Despite its increased adoption, it is still unknown whether or not the program improves healthcare access, outcomes, and affordability for cancer survivors. Methods: We performed a cross-sectional study of Medicare beneficiaries aged ≥ 65 years with a self-reported history of cancer from the 2019 National Health Interview Survey. We used multivariable logistic regression to evaluate the association between Medicare program type (Medicare Advantage vs. traditional Medicare) and measures of healthcare access, acute care utilization, and affordability. Results: We identified 4451 beneficiaries with a history of cancer, corresponding to 26.6 million weighted cancer survivors in 2019. Of the beneficiaries, 35.8% were enrolled in Medicare Advantage, whereas 64.2% were enrolled in traditional Medicare. The age, sex, racial and ethnic composition, household income, primary site of cancer, and comorbidity burden of Medicare Advantage and traditional Medicare beneficiaries were similar. In the adjusted analysis, there were no differences in healthcare access or acute care utilization between traditional Medicare and Medicare Advantage beneficiaries. However, cancer survivors enrolled in Medicare Advantage were more likely to worry about (34.3% vs. 29.4%; aOR, 1.3 (95% CI, 1.1–1.5)) or have problems paying (13.6% vs. 11.1%; aOR, 1.4 (95% CI, 1.1–1.8)) medical bills. Conclusions: We found no evidence that Medicare Advantage beneficiaries with cancer had better healthcare access, affordability, or acute care utilization than traditional Medicare beneficiaries did. Furthermore, Medicare Advantage beneficiaries were more likely to report financial strain and have difficulty paying for their medical bills than were those with traditional Medicare. Despite the generous benefits and attractive incentives, Medicare Advantage plans may not be more cost-effective than traditional Medicare is for cancer survivors. Our study informs ongoing congressional deliberations to re-evaluate the role of Medicare Advantage in promoting equity among beneficiaries with cancer.

7 March 2023 in Digestive Diseases and Sciences
Verified
Journal Article
Open access
PDF file
FJFaraz Jafri
Faraz Jafri
ASAlexis de Montfort Shepherd
Alexis de Montfort Shepherd
PRPralahad Raman
Pralahad Raman
TVThomas Chandy Varkey
Thomas Chandy Varkey
CHCharles Hyman
Charles Hyman
DADeepak Agrawal
Deepak Agrawal

1 January 2022 in Emergency Care Journal
Verified
Journal Article
Open access
PDF file
KAKartik Akkihal
Kartik Akkihal
EAEdy C. Adams
Edy C. Adams
SKSoman Khan
Soman Khan
FJFaraz Jafri
Faraz Jafri
JTJorge Taboada
Jorge Taboada
TVThomas Chandy Varkey
Thomas Chandy Varkey
Patients often present to the emergency department with nonspecific complaints of lumbar back pain. Because of the nature of the emergency department, the lack of knowledge or time on the part of providers, and the high levels of quick decision making, unnecessary imaging studies are often ordered to provide care for the patient's emotional and perceived physical needs. This narrative review will present a hypothetical typical standardized case of a patient presenting with lower back pain, examine the current evidence and recommendations from the major ruling bodies in internal medicine, neurology, neurosurgery, and radiology, evaluate the major statements released by the Choosing Wisely campaign, and finally, present a new diagnostic decision tree for the management of lumbar back pain.

23 March 2024 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
FJFaraz Jafri
Faraz Jafri
SSShahbaz Saad
Shahbaz Saad
HRHamna Riaz
Hamna Riaz
FSFarah Saleem
Farah Saleem
SGSara Gottesman
Sara Gottesman